share_log

Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial

Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial

康泰納菲(Cantor Fitzgerald)維持對安進的超重評級,目標價爲405美元,預計2024年營業收入爲332億美元;強調管線風險和AMG-133第1期臨床試驗中骨礦密度下降4%。
Benzinga ·  2024/11/13 03:21  · 評級/大行評級

Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial

坎託·菲茨傑拉德維持對安進的增持評級,目標股價爲405美元,預計2024年收入爲332億美元;在 AMG-133 第一階段試驗中強調管道風險和-4%的BMD損失

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論